The Department of Biotechnology is implementing a bilateral programme called Indo-US Vaccine Action Programme, (VAP) with National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), USA since July, 1987. The program supports a broad spectrum of activities relating to new and improved vaccines. The program was designed to encompass laboratory-based research, evaluation of candidate vaccine development, testing for clinical development, vaccine quality control, delivery of vaccines etc. All work is carried out within areas designated as VAP priorities by the VAP Joint Working Group (JWG) which is composed of eminent scientists and policymakers from both the countries.
The 29th Joint Working Group meeting of VAP is scheduled to be held on April 11-12, 2017 at NIAID, NIH, USA. During this two day meeting a Joint Statement for further extension of VAP programme for a period of five years is also proposed to be signed between Prof. K. VijayRaghavan, Secretary DBT and Dr. Anthony S. Fauci, Director, NIAID, NIH, USA.